We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current OTLK market cap is 42.61M. The company's latest EPS is USD -2.3540 and P/E is -0.59.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -10.32M | -18.97M | -19.62M | -22.89M | -21.64M |
| Net Income | -11.18M | -114.29M | 44.41M | 5.69M | 17.38M |
| Year End September 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -36.84M | -51.77M | -63.12M | -53.14M | -71.8M |
| Net Income | -48.87M | -53.16M | -66.05M | -58.98M | -75.37M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 21.69M | 59.03M | 47.09M | 28.82M | 17.01M |
| Total Liabilities | 46.03M | 193.27M | 130.77M | 101.9M | 67.3M |
| Total Equity | -24.34M | -134.24M | -83.67M | -73.08M | -50.29M |
| Year End September 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 19.73M | 22.81M | 28.53M | 32.3M | 28.82M |
| Total Liabilities | 16.91M | 18.2M | 19.79M | 46.74M | 101.9M |
| Total Equity | 2.83M | 4.61M | 8.74M | -14.44M | -73.08M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -13.03M | -32.3M | -51.81M | -68.79M | -10.97M |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | -3k | 56.14M | 60.44M | 60.33M | 1.74M |
| Year End September 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -31.79M | -54.25M | -56.67M | -42.97M | -68.79M |
| Investing | -900k | N/A | N/A | N/A | N/A |
| Financing | 37.21M | 56.19M | 59.59M | 48.97M | 60.33M |
| Market Cap | 42.61M |
| Price to Earnings Ratio | -0.59 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 3 |
| Price to Book Ratio | -0.61 |
| Dividend Yield | - |
| Shares Outstanding | 32.02M |
| Average Volume (1 week) | 397.95k |
| Average Volume (1 Month) | 441.59k |
| 52 Week Change | -84.42% |
| 52 Week High | 9.2899 |
| 52 Week Low | 0.87 |
| Spread (Intraday) | 0.01 (0.75%) |
| Company Name | Outlook Therapeutics Inc |
| Address |
800 north state street dover, delaware 19901 |
| Website | https://www.outlooktherapeutics.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
